Sunday, October 12, 2008 - 7:04AM EST

Clinical Trials

1. Satisfaction with current migraine therapy: experience from 3 centers in US and Sweden.

Author
Bigal M; Rapoport A; Aurora S; Sheftell F; Tepper S; Dahlof C;
Institution
Albert Einstein College of Medicine--Neurology, Bronx, NY 10461, USA.
Journal
Headache. 2007 Apr;47(4):475-9.
Abstract URL
Click here to view abstract

2. Efficacy of lisinopril in migraine prophylaxis--an open label study.

Author
Schuh-Hofer S; Flach U; Meisel A; Israel H; Reuter U; Arnold G;
Institution
Department of Neurology, Universitatsklinikum Tuebingen, Tuebingen, Germany.sigrid.schuh-hofer@gmx.net
Journal
Eur J Neurol. 2007 Jun;14(6):701-3.
Abstract URL
Click here to view abstract

3. Dihydroergotamine for early and late treatment of migraine with cutaneous allodynia: an open-label pilot trial.

Author
Silberstein SD; Young WB; Hopkins MM; Gebeline-Myers C; Bradley KC;
Institution
Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Journal
Headache. 2007 Jun;47(6):878-85.
Abstract URL
Click here to view abstract

4. Open-label, long-term tolerability of naratriptan for short-term prevention of menstrually related migraine.

Author
Brandes JL; Smith T; Diamond M; Ames MH;
Institution
Department of Neurology, Vanderbilt University School of Medicine, Nashville, TN, USA.
Journal
Headache. 2007 Jun;47(6):886-94.
Abstract URL
Click here to view abstract

5. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.

Author
Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
Institution
Swedish Pain Center, Seattle, WA 98104, USA.
Journal
Headache. 2007 Apr;47(4):486-99.
Abstract URL
Click here to view abstract

6. Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial.

Author
Winner P; Linder SL; Lipton RB; Almas M; Parsons B; Pitman V;
Institution
Nova Southeastern University, Fort Lauderdale, FL 33407, USA.
Journal
Headache. 2007 Apr;47(4):511-8.
Abstract URL
Click here to view abstract

7. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS).

Author
Freitag FG; Finlayson G; Rapoport AM; Elkind AH; Diamond ML; Unger JR; Fisher AC; Armstrong RB; Hulihan JF; Greenberg SJ;
Institution
Diamond Headache Clinic, Ltd, Chicago, IL 60614, USA.
Journal
Headache. 2007 Apr;47(4):519-30.
Abstract URL
Click here to view abstract

8. Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies.

Author
Mannix LK; Loder E; Nett R; Mueller L; Rodgers A; Hustad CM; Ramsey KE; Skobieranda F;
Institution
Headache Associates and ClinExcel Research, West Chester, OH 45069, USA. lkmannixmd@aol.com
Journal
Cephalalgia. 2007 May;27(5):414-21.
Abstract URL
Click here to view abstract

9. Effectiveness of yoga therapy in the treatment of migraine without aura: a randomized controlled trial.

Author
John PJ; Sharma N; Sharma CM; Kankane A;
Institution
Department of Zoology, University of Rajasthan, Jaipur, Rajasthan, India.
Journal
Headache. 2007 May;47(5):654-61.
Abstract URL
Click here to view abstract

10. Efficacy of eletriptan in migraine-related functional impairment: functional and work productivity outcomes.

Author
Silberstein SD; Cady RK; Sheftell FD; Almas M; Parsons B; Albert KS;
Institution
Jefferson Headache Center, Philadelphia, PA 19107, USA.
Journal
Headache. 2007 May;47(5):673-82.
Abstract URL
Click here to view abstract
Pages: 1 2 3 4 5 6